| 000 | 01810 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250513223635.0 | ||
| 264 | 0 | _c20001207 | |
| 008 | 200012s 0 0 eng d | ||
| 022 | _a0098-1532 | ||
| 024 | 7 |
_a10.1002/1096-911x(20001101)35:5<449::aid-mpo2>3.0.co;2-x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLo Nigro, L | |
| 245 | 0 | 0 |
_aAcute neurotoxicity in children with B-lineage acute lymphoblastic leukemia (B-ALL) treated with intermediate risk protocols. _h[electronic resource] |
| 260 |
_bMedical and pediatric oncology _cNov 2000 |
||
| 300 |
_a449-55 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 |
_aAnti-Inflammatory Agents _xadverse effects |
| 650 | 0 | 4 |
_aAntimetabolites, Antineoplastic _xadverse effects |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xadverse effects |
| 650 | 0 | 4 |
_aBurkitt Lymphoma _xdrug therapy |
| 650 | 0 | 4 |
_aCentral Nervous System Diseases _xchemically induced |
| 650 | 0 | 4 | _aChild |
| 650 | 0 | 4 | _aChild, Preschool |
| 650 | 0 | 4 | _aCombined Modality Therapy |
| 650 | 0 | 4 |
_aCytarabine _xadverse effects |
| 650 | 0 | 4 | _aDisease-Free Survival |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHydrocortisone _xadverse effects |
| 650 | 0 | 4 | _aIncidence |
| 650 | 0 | 4 | _aInfant |
| 650 | 0 | 4 | _aInjections, Spinal |
| 650 | 0 | 4 |
_aItaly _xepidemiology |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMethotrexate _xadverse effects |
| 650 | 0 | 4 | _aRadiotherapy, Adjuvant |
| 650 | 0 | 4 | _aRetrospective Studies |
| 700 | 1 | _aDi Cataldo, A | |
| 700 | 1 | _aSchiliro, G | |
| 773 | 0 |
_tMedical and pediatric oncology _gvol. 35 _gno. 5 _gp. 449-55 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/1096-911x(20001101)35:5<449::aid-mpo2>3.0.co;2-x _zAvailable from publisher's website |
| 999 |
_c11012302 _d11012302 |
||